Literature DB >> 7577371

Current status of radiation sensitization by fluoropyrimidines.

A T Pu1, J M Robertson, T S Lawrence.   

Abstract

Numerous clinical studies suggest that the combination of the fluoropyridimine fluorouracil and radiation is a more effective treatment for many cancers, especially gastrointestinal tumors, than is either modality alone. Also, the combination of fluorouracil and radiation has greatly expanded the possibilities for organ-preserving treatments, for example, in patients with bladder cancer. Another fluoropyridimine, floxuridine, administered via the hepatic artery, has been used in combination with irradiation in the treatment of patients with intrahepatic cancers and may prolong survival in patients with unresectable hepatobiliary malignancies. The beneficial effects of combining fluoropyrimidines and radiation are thought to be due to radiosensitization. More studies are needed to clarify the mechanism(s) of radiosensitization so as to optimize regimens in which the fluoropyrimidines are used.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7577371

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  3 in total

1.  HPV16-E7 expression causes fluorodeoxyuridine-mediated radiosensitization in SW620 human colon cancer cells.

Authors:  M D Axelson; M A Davis; S P Ethier; T S Lawrence
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

2.  Effects of 5-fluorouracil on cell cycle arrest and toxicity induced by X-irradiation in normal mammalian cells.

Authors:  U Nylén; E Cekan; G B Jonasson; F Lewin; S Skog
Journal:  Cell Prolif       Date:  2001-04       Impact factor: 6.831

3.  Aortic pseudoaneurysm formation following concurrent chemoradiotherapy and metallic stent insertion in a patient with esophageal cancer.

Authors:  Pei-Yu Hou; Chung-Jen Teng; Chen-Shuan Chung; Chao-Yu Liu; Chun-Chieh Huang; Miu-Hsiang Chang; Pei-Wei Shueng; Chen-Hsi Hsieh
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.